351 related articles for article (PubMed ID: 15153169)
1. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C.
Lin OS; Keeffe EB; Sanders GD; Owens DK
Aliment Pharmacol Ther; 2004 Jun; 19(11):1159-72. PubMed ID: 15153169
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of suppressing hepatitis B virus DNA in immune tolerant patients to prevent hepatocellular carcinoma and cirrhosis.
Enriquez AD; Campbell MS; Reddy KR
Aliment Pharmacol Ther; 2007 Aug; 26(3):383-91. PubMed ID: 17635373
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting.
Manser R; Dalton A; Carter R; Byrnes G; Elwood M; Campbell DA
Lung Cancer; 2005 May; 48(2):171-85. PubMed ID: 15829317
[TBL] [Abstract][Full Text] [Related]
4. Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence.
Hung HF; Chen TH
Vaccine; 2009 Nov; 27(48):6770-6. PubMed ID: 19735755
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of botulinum toxin a versus anticholinergic medications for idiopathic urge incontinence.
Wu JM; Siddiqui NY; Amundsen CL; Myers ER; Havrilesky LJ; Visco AG
J Urol; 2009 May; 181(5):2181-6. PubMed ID: 19296983
[TBL] [Abstract][Full Text] [Related]
6. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis.
Arguedas MR; Chen VK; Eloubeidi MA; Fallon MB
Am J Gastroenterol; 2003 Mar; 98(3):679-90. PubMed ID: 12650806
[TBL] [Abstract][Full Text] [Related]
7. Hepatocellular carcinoma screening in patients waiting for liver transplantation: a decision analytic model.
Saab S; Ly D; Nieto J; Kanwal F; Lu D; Raman S; Amado R; Nuesse B; Durazo F; Han S; Farmer DG; Ghobrial RM; Yersiz H; Chen P; Schwegel K; Goldstein LI; Tong M; Busuttil RW
Liver Transpl; 2003 Jul; 9(7):672-81. PubMed ID: 12827551
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of screening, surveillance, and primary prophylaxis strategies for esophageal varices.
Arguedas MR; Heudebert GR; Eloubeidi MA; Abrams GA; Fallon MB
Am J Gastroenterol; 2002 Sep; 97(9):2441-52. PubMed ID: 12358270
[TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C viral infection in the United States.
Arguedas MR; Heudebert GR; Fallon MB; Stinnett AA
Am J Gastroenterol; 2002 Mar; 97(3):721-8. PubMed ID: 11922569
[TBL] [Abstract][Full Text] [Related]
10. Routine hepatitis C virus screening in pregnancy: a cost-effectiveness analysis.
Plunkett BA; Grobman WA
Am J Obstet Gynecol; 2005 Apr; 192(4):1153-61. PubMed ID: 15846195
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy.
Sanders GD; Bayoumi AM; Sundaram V; Bilir SP; Neukermans CP; Rydzak CE; Douglass LR; Lazzeroni LC; Holodniy M; Owens DK
N Engl J Med; 2005 Feb; 352(6):570-85. PubMed ID: 15703422
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of a community-based screening programme for chronic atrial fibrillation in Japan.
Maeda K; Shimbo T; Fukui T
J Med Screen; 2004; 11(2):97-102. PubMed ID: 15153326
[TBL] [Abstract][Full Text] [Related]
13. Application of surveillance programs for hepatocellular carcinoma in the Asia-Pacific Region.
Amarapurkar D; Han KH; Chan HL; Ueno Y;
J Gastroenterol Hepatol; 2009 Jun; 24(6):955-61. PubMed ID: 19383082
[TBL] [Abstract][Full Text] [Related]
14. The cost-effectiveness of alternative strategies against HBV in Italy.
Ruggeri M; Cicchetti A; Gasbarrini A
Health Policy; 2011 Sep; 102(1):72-80. PubMed ID: 21035229
[TBL] [Abstract][Full Text] [Related]
15. The cost-effectiveness of cervical screening in Australia: what is the impact of screening at different intervals or over a different age range?
Anderson R; Haas M; Shanahan M
Aust N Z J Public Health; 2008 Feb; 32(1):43-52. PubMed ID: 18290913
[TBL] [Abstract][Full Text] [Related]
16. Antiviral therapy for hepatitis B-related liver cancer prevention is more cost-effective than cancer screening.
Robotin MC; Kansil M; Howard K; George J; Tipper S; Dore GJ; Levy M; Penman AG
J Hepatol; 2009 May; 50(5):990-8. PubMed ID: 19303657
[TBL] [Abstract][Full Text] [Related]
17. [Screening for the early diagnosis of hepatocellular carcinoma: cost-effectiveness analysis].
Bolondi L; Gaiani S; Casali A; Serra C; Piscaglia F
Radiol Med; 1997; 94(1-2):4-7. PubMed ID: 9424649
[TBL] [Abstract][Full Text] [Related]
18. Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis.
Rothberg MB; Rose DN
Am J Med; 2005 Jan; 118(1):68-77. PubMed ID: 15639212
[TBL] [Abstract][Full Text] [Related]
19. Costs and clinical outcomes of primary prophylaxis of variceal bleeding in patients with hepatic cirrhosis: a decision analytic model.
Saab S; DeRosa V; Nieto J; Durazo F; Han S; Roth B
Am J Gastroenterol; 2003 Apr; 98(4):763-70. PubMed ID: 12738453
[TBL] [Abstract][Full Text] [Related]
20. Screening and early treatment of migrants for chronic hepatitis B virus infection is cost-effective.
Veldhuijzen IK; Toy M; Hahné SJ; De Wit GA; Schalm SW; de Man RA; Richardus JH
Gastroenterology; 2010 Feb; 138(2):522-30. PubMed ID: 19879275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
